# US 2025/0051326 A1 · Crystalline forms of cftr modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0051326 A1
- Document ID: US20250051326A1
- Status: Published application
- Kind: A1
- Application number: 18/493,667
- Filed: 2023-10-24
- Published: 2025-02-13
- Earliest claimed: 2019-08-14
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Yi Shi; Kevin J. Gagnon; Jicong Li; Jennifer Lu; Ales Medek; Muna Shrestha; Michael Waldo; Beili Zhang; Carl L. Zwicker; Corey Don Anderson; Jeremy J. Clemens; Thomas Cleveland; Timothy Richard Coon; Bryan Frieman; Peter Grootenhuis; Sara Sabina Hadida Ruah; Jason McCartney; Mark Thomas Miller; Prasuna Paraselli; Fabrice Pierre; Sara E. Swift; Jinglan Zhou
- Web page: https://patentgrep.com/patent/US20250051326A1

## CPC

- C07D 471/08: Bridged systems
- C07D 513/22: in which the condensed system contains four or more hetero rings
- A61P 11/00: Drugs for disorders of the respiratory system
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

## Claims

### Claim 1

A substantially crystalline Compound I calcium salt hydrate Form A

### Claim at position 2

-8. (canceled)

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the Compound I calcium salt hydrate Form A according to claim 1.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, further comprising one or more additional CFTR modulating compounds.

### Claim at position 5

-12. (canceled)

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the one or more additional CFTR modulating compounds are selected from

### Claim 14 (depends on 1)

A method of treating cystic fibrosis comprising administering the Compound I calcium salt hydrate Form A according to claim 1 to a subject in need thereof.

### Claim 15 (depends on 14)

The method of treating cystic fibrosis according to claim 14, wherein the Compound I calcium salt hydrate Form A is administered with one or more additional CFTR modulating compounds.

### Claim 16 (depends on 15)

The method of treating cystic fibrosis according to claim 15, wherein the one or more additional CFTR modulating compound are selected from

### Claim 17 (depends on 1)

A method of preparing the Compound I calcium salt hydrate Form A according to claim 1, comprising:
(a) charging Compound I Form A and calcium methoxide (Ca(OMe)2) with IPA/H2O
(b) heating to 70° C., and
(c) isolating the resulting solids,
to provide Compound I calcium salt hydrate Form A.

### Claim 18

Compound I calcium salt hydrate Form A
characterized by an X-ray powder diffractogram (XRPD) having signals at 4.2±0.2 degrees two-theta, 18.0±0.2 degrees two-theta, and 19.7±0.2 degrees two-theta.

### Claim 19 (depends on 18)

The Compound I calcium salt hydrate Form A according to claim 18, characterized by an X-ray powder diffractogram (XRPD) having (a) signals at 4.2±0.2 degrees two-theta, 18.0±0.2 degrees two-theta, and 19.7±0.2 degrees two-theta; and (b) signals at one or more of 10.5±0.2 degrees two-theta, 10.6±0.2 degrees two-theta, and 17.8±0.2 degrees two-theta.

### Claim 20 (depends on 18)

The Compound I calcium salt hydrate Form A according to claim 18, characterized by an X-ray powder diffractogram (XRPD) having (a) signals at 4.2±0.2 degrees two-theta, 18.0±0.2 degrees two-theta, and 19.7±0.2 degrees two-theta; and (b) signals at two or more of 10.5±0.2 degrees two-theta, 10.6±0.2 degrees two-theta, and 17.8±0.2 degrees two-theta.

### Claim 21 (depends on 18)

The Compound I calcium salt hydrate Form A according to claim 18, characterized by an X-ray powder diffractogram (XRPD) having (a) signals at 4.2±0.2 degrees two-theta, 18.0±0.2 degrees two-theta, and 19.7±0.2 degrees two-theta; and (b) signals at 10.5±0.2 degrees two-theta, 10.6±0.2 degrees two-theta, and 17.8±0.2 degrees two-theta.

### Claim 22 (depends on 1)

The Compound I calcium salt hydrate Form A according to claim 1, characterized by an X-ray powder diffractogram substantially similar to FIG. 6.

### Claim 23 (depends on 1)

The Compound I calcium salt hydrate Form A according to claim 1, characterized by a monoclinic crystal system, a C2 space group, and unit cell dimensions measured at 100 K on a Bruker diffractometer equipped with Cu Kα radiation (λ=1.5478 Å) of
a
11.13 ± .01 Å
α
90º
b
13.77 ± .01 Å
β
101.93 ± .01º
c
22.21 ± .01 Å
γ
90º.

### Claim 24

Compound I calcium salt hydrate Form A
characterized by a 13C solid state nuclear magnetic resonance (13C ssNMR) spectrum with a peak at 17.0±0.2 ppm.

### Claim 25 (depends on 24)

The Compound I calcium salt hydrate Form A according to claim 24, characterized by a 13C ssNMR spectrum with a peak at 7.8±0.2 ppm.

### Claim 26 (depends on 24)

The Compound I calcium salt hydrate Form A according to claim 24, characterized by a 13C ssNMR spectrum with peaks at 17.0±0.2 ppm and 7.8±0.2 ppm.

### Claim 27 (depends on 24)

The Compound I calcium salt hydrate Form A according to claim 24, characterized by a 13C ssNMR spectrum substantially similar to FIG. 7.

### Claim 28 (depends on 9)

The pharmaceutical composition according to claim 9, wherein at least 85% of the Compound I is Compound I calcium salt hydrate Form A.

### Claim 29 (depends on 9)

The pharmaceutical composition according to claim 9, wherein at least 95% of the Compound I is Compound I calcium salt hydrate Form A.
